Hybrid capture 2 test results after an initial equivocal RLU/CO value are dependent on age

American Journal of Clinical Pathology

Volumn 139, Issue 5, 2013, Pages 605-610

  Elkins, Camille T ^a   De Vries, Christiaan E ^a   Stephens, Julie ^a   Suarez, Adrian A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Age; Cervical intraepithelial neoplasia; Human papillomavirus; Hybrid Capture 2; RLU CO

Indexed keywords

ADOLESCENT; ADULT; AGE DETERMINATION; ARTICLE; CANCER GRADING; CLASSIFICATION ALGORITHM; FEMALE; FOLLOW UP; HUMAN; HYBRID CAPTURE 2; LABORATORY TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL LABORATORY TECHNIQUES; CYTODIAGNOSIS; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84878039339     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPARHTB40DTVFV     Document Type: Article

References (24)

1. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-383.
2. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
3. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
4. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol. 2010;134:193-199.
5. HC2 HPV DNA Test [package insert]. Gaithersburg, MD: Digene; 2007.
6. Rebolj M, Bonde J, Njor SH, et al. Human papillomavirus testing in primary cervical screening and the cut-off level for Hybrid Capture 2 tests: systematic review. BMJ. 2011;342:d2757.
7. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492-501.
8. Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive Hybrid Capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol. 2010;48:554-558.
9. Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol. 2007;16:125-129.
10. Knoepp SM, Kuebler DL, Wilbur DC. Correlation between Hybrid Capture II high-risk HPV DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/histologic review of 367 cases. Cancer Cytopathol. 2010;118:209-217.
11. Ordi J, Alonso I, Torné A, et al. Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol. 2005;99:313-319.
12. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002;94:102-107.
13. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
14. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500.
15. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
16. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677-2684.
17. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1808-1816.
18. De Vries CE, Shen R, Stephens J, et al. Equivocal and weakly positive Hybrid Capture 2 tests in women aged 50 and older. Diagn Cytopathol. 2011;40:708-712.
19. Wheeler CM, Hunt WC, Cuzick J, et al. A population-based study of HPV genotype prevalence in the United States: baseline measures prior to mass HPV vaccination [published online June 20, 2012]. Int J Cancer. 2013;132:198-207. doi:10.1002/ijc.27608.
20. Wright TC Jr., Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206:46.e1-46.e11.
21. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-520.
22. Jarboe EA, Venkat P, Hirsch MS, et al. A weakly positive human papilloma virus Hybrid Capture II result correlates with a significant lower risk of cervical intraepithelial neoplasia 2, 3 after atypical squamous cells of undetermined significance cytology. J Low Genit Tract Dis. 2010;14:174-178.
23. Siddiqi A, Spataro M, McIntire H, et al. Hybrid Capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens. Cancer. 2009;117:318-325.
24. Qureshi MN, Bolick D, Ringer PJ, et al. HPV testing in liquid cytology specimens: comparison of analytic sensitivity and specificity for in situ hybridization and chemiluminescent nucleic acid testing. Acta Cytol. 2005;49:120-126.